Cerevel Therapeutics Holdings, Inc. financial data

Location
222 Jacobs Street, Suite 200, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.03K % -20.8%
Debt-to-equity 120 % +47.4%
Return On Equity -98.9 % -28.2%
Return On Assets -45.1 % -5.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 182M shares +16%
Common Stock, Shares, Outstanding 182M shares +16%
Entity Public Float 2.2B USD +39.6%
Common Stock, Value, Issued 18K USD +12.5%
Weighted Average Number of Shares Outstanding, Basic 182M shares +15.9%
Weighted Average Number of Shares Outstanding, Diluted 182M shares +15.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 363M USD +19.6%
General and Administrative Expense 127M USD +39.4%
Operating Income (Loss) -490M USD -24.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -460M USD -18.8%
Income Tax Expense (Benefit) 556K USD +62.4%
Net Income (Loss) Attributable to Parent -460M USD -18.8%
Earnings Per Share, Basic -3 USD/shares -7.91%
Earnings Per Share, Diluted -3 USD/shares -7.91%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 320M USD +108%
Other Assets, Current 77K USD -94.4%
Assets, Current 860M USD +2.24%
Property, Plant and Equipment, Net 24.9M USD -7.69%
Operating Lease, Right-of-Use Asset 19.7M USD -8.24%
Other Assets, Noncurrent 2.62M USD -18.4%
Assets 1.13B USD +21.2%
Accounts Payable, Current 10.8M USD +48.2%
Employee-related Liabilities, Current 6.94M USD +8.89%
Liabilities, Current 84.1M USD +33.6%
Operating Lease, Liability, Noncurrent 26.9M USD -11.6%
Liabilities 563M USD +12.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.09M USD -130%
Retained Earnings (Accumulated Deficit) -1.53B USD -43%
Stockholders' Equity Attributable to Parent 564M USD +30.7%
Liabilities and Equity 1.13B USD +21.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -120M USD -26.1%
Net Cash Provided by (Used in) Financing Activities 4.48M USD +212%
Net Cash Provided by (Used in) Investing Activities 19.2M USD -82.7%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 182M shares +16%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 322M USD +107%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4.31M USD +0.56%
Deferred Tax Assets, Valuation Allowance 377M USD +53.6%
Deferred Tax Assets, Gross 388M USD +51.2%
Operating Lease, Liability 31.2M USD -8.5%
Payments to Acquire Property, Plant, and Equipment 271K USD -19.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -465M USD -21.6%
Lessee, Operating Lease, Liability, to be Paid 41.8M USD -12.7%
Operating Lease, Liability, Current 3.52M USD +16.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 6.46M USD +2.67%
Lessee, Operating Lease, Liability, to be Paid, Year One 6.29M USD +3.17%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 10.6M USD -23.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 6.66M USD +3.16%
Deferred Tax Assets, Operating Loss Carryforwards 146M USD +20.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 6.86M USD +3%
Additional Paid in Capital 2.1B USD +39.9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 1.54M USD +16.7%
Deferred Tax Assets, Net of Valuation Allowance 11.5M USD -0.32%
Share-based Payment Arrangement, Expense 77.8M USD +81.6%
Interest Expense 10.6M USD +0.61%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%